We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

61 hedge funds and large institutions have $2.45M invested in Oncolytics Biotech in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

9% more funds holding

Funds holding: 56 → 61 (+5)

0.02% less ownership

Funds ownership: 2.81% → 2.79% (-0.02%)

35% less capital invested

Capital invested by funds: $3.77M → $2.45M (-$1.32M)

Holders
61
Holders Change
+5
Holders Change %
+8.93%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
9
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Connective Capital Management
California
+$162K
2
XT
XTX Topco
Cayman Islands
+$85K
3
VF
Virtu Financial
New York
+$84.2K
4
TAM
Tocqueville Asset Management
New York
+$77.8K
5
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
+$54K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$535K
2
QC
Quadrature Capital
United Kingdom
-$146K
3
Marshall Wace
Marshall Wace
United Kingdom
-$66.8K
4
Goldman Sachs
Goldman Sachs
New York
-$41.9K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$35K
Name Holding Trade Value Shares
Change 		Change in
Stake
VPF
26
Vantage Point Financial
Illinois
$26K – – –
Bank of Montreal
27
Bank of Montreal
Ontario, Canada
$24.4K +$135 +125 +0.3%
BAM
28
Brave Asset Management
New Jersey
$21.9K – – –
National Bank of Canada
29
National Bank of Canada
Quebec, Canada
$21.7K – – –
PI
30
PFG Investments
New York
$20K +$2.59K +2,400 +12%
UBS Group
31
UBS Group
Switzerland
$20K – – –
AC
32
AlphaCore Capital
California
$19.7K +$24.3K +22,500 New
Rockefeller Capital Management
33
Rockefeller Capital Management
New York
$18.3K – – –
PAS
34
Professional Advisory Services
Florida
$17K – – –
Jane Street
35
Jane Street
New York
$14.2K -$7.15K -6,615 -33%
PNC Financial Services Group
36
PNC Financial Services Group
Pennsylvania
$13.2K – – –
Creative Planning
37
Creative Planning
Kansas
$11.7K – – –
HA
38
Huntleigh Advisors
Missouri
$11.4K +$14K +13,000 New
AFP
39
Ausdal Financial Partners
Iowa
$10.5K – – –
HF
40
HRT Financial
New York
$10K -$8.42K -7,790 -39%
KWM
41
Kingsview Wealth Management
Oregon
$9.8K – – –
Cerity Partners
42
Cerity Partners
New York
$8.74K – – –
AF
43
Allworth Financial
California
$7.39K – – –
VNA
44
Valley National Advisers
Pennsylvania
$6K – – –
CMA
45
Cedar Mountain Advisors
Oregon
$4.94K – – –
Osaic Holdings
46
Osaic Holdings
Arizona
$4.84K +$5.94K +5,500 +8,730%
Wells Fargo
47
Wells Fargo
California
$4.72K +$1.08K +1,000 +23%
AWM
48
Activest Wealth Management
Florida
$4.37K – – –
BlackRock
49
BlackRock
New York
$2.62K – – –
Jones Financial Companies
50
Jones Financial Companies
Missouri
$1.79K – – –
1
2
3

ONCY Hedge Fund Activity: Q4 2025 in Review

61 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2025, worth a combined $2.45M — down 35% from $3.77M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ONCY positions and 7 closed out — a net gain of 6 holders — while 9 added to existing stakes and 5 trimmed.

The largest buyer was Connective Capital Management, opening a new position worth an estimated $162K. The largest seller was Citadel Advisors, exiting entirely with an estimated $535K sold.

  • 61 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2025, up from 56 in Q3 2025.
  • Funds reported $2.45M of Oncolytics Biotech stock for Q4 2025, down 35% quarter-over-quarter.
  • 13 funds opened new Oncolytics Biotech positions in Q4 2025 and 7 closed out, a net change of +6 holders.
  • The largest Oncolytics Biotech buyer in Q4 2025 was Connective Capital Management, an estimated $162K added.
  • The largest Oncolytics Biotech seller in Q4 2025 was Citadel Advisors, an estimated $535K sold.

Based on aggregated 13F filings for Q4 2025.